Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2013-003563-58-GB
EUCTR2013-003563-58-GB
Active, not recruiting
Phase 1

A Phase II, single-centre exploratory study to assess the value of hypoxia imaging with [18F]HX4 PET/CT in predicting outcome for patients with squamous cell carcinoma of head and neck and non-small cell lung cancer undergoing radical radiotherapy with curative intent (OXYPET Study) - [18F]HX4 PET/CT Imaging for Detection of Hypoxia (OXYPET Study) V1

ottingham University Hospitals NHS Trust0 sites3 target enrollmentDecember 9, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
ottingham University Hospitals NHS Trust
Enrollment
3
Status
Active, not recruiting
Last Updated
7 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 9, 2013
End Date
July 25, 2017
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
ottingham University Hospitals NHS Trust

Eligibility Criteria

Inclusion Criteria

  • •Patients with:
  • •(a) biopsy proven non\-small cell carcinoma of the lung \>2\.5 cm in size with any T and N status but M0 who have elected to undergo radical radiotherapy or chemo\-radiotherapy with curative intent or
  • •(b)squamous cell carcinoma of the upper aerodigestive tract (excluding oesophagus) with a primary tumour or nodal mass \>2\.5 cm in size, with any T and N status but M0 who have elected to undergo radical radiotherapy or chemo\-radiotherapy with curative intent.
  • •Participant must be willing and able to give informed consent for participation in the study.
  • •Patients must be 18 years old or above.
  • •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\.
  • •Have adequate renal function, defined by creatinine clearance of \>30 mL/min.
  • •Able to remain still in the supine position on the scanner bed for the 40 minute duration of the examination.
  • •Able (in the Investigators opinion) and willing to comply with all study requirements.
  • •Willing to allow his or her General Practitioner and hospital consultant to be notified of participation in the study.

Exclusion Criteria

  • •Female participant who is pregnant, lactating or planning pregnancy during the course of the study.
  • •Chronic kidney disease stage III or worse, as defined by the NKF clinical practice guidelines.
  • •Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of involvement in the study, or may influence the result of the study, or the participant’s ability to participate in the study.
  • •Participants who have been involved in another research study involving an investigational product in the past 12 weeks.
  • •Previous surgery or radiotherapy to the upper aerodigestive tract or lung, which in the opinion of the Investigators could compromise the data.
  • •Patient is a prisoner.
  • •Previous cancer diagnosis.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A Phase IIa, Single-Center Study, Investigating the Short-Term Renal Hemodynamic Effects, Safety and Pharmacokinetics/Pharmacodynamics of Oral Tolvaptan (OPC-41061) in Subjects with Autosomal Dominant Polycystic Kidney Disease at Various Stages of Renal FunctioAutosomal Dominant Polycystic Kidney Disease (ADPKD)MedDRA version: 12.1Level: LLTClassification code 10036046Term: Polycystic kidney, autosomal dominant
EUCTR2010-019025-33-NLOtsuka Pharmaceutical Development Commercialization, Inc.36
Completed
Phase 2
A Phase 2a, Single-Center Study Investigating the Short-Term Renal Hemodynamic Effects, Safety and Pharmacokinetics/ Pharmacodynamics of Oral Tolvaptan in Subjects with Autosomal Dominant Polycystic Kidney Disease at Various Stages of Renal Functio
NL-OMON34527Covance36
Active, not recruiting
Phase 1
A Phase II, Multicenter, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adults Unprimed and Primed with MF59-adjuvanted or Non-adjuvanted H5N3 Influenza Vaccines.
EUCTR2006-005203-33-GBovartis Vaccines and Diagnostics GmbH & Co. KG60
Active, not recruiting
Phase 1
A phase 2 trial for patients with locally advanced or metastatic bile duct cancer investigating treatment with cisplatin and gemcitabine with or without tocilizumab.First-line treatment in patients with locally advanced or metastatic biliary tract cancer, inoperable due to extension of the disease.MedDRA version: 25.1Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10008596Term: Cholangiocarcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10074878Term: Hilar cholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10074879Term: Extrahepatic cholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10077846Term: Cholangiocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-004826-27-DKDepartment of Oncology, Herlev & Gentofte Hospital166
Completed
Not Applicable
Study to Evaluate the Efficacy of Lazertinib in Patients with Non-small cell lung cancer(NSCLC) Who Harboring EGFR T790M Mutation Detected by Bronchoalveolar Lavage Liquid (BALiquid)
KCT0006841Konkuk University Medical Center32